圣湘生物科技股份有限公司 二〇二五年五月 圣湘生物科技股份有限公司（688289）2024 年年度股东大会会议资料 议案三：圣湘生物科技股份有限公司关于 2025 年度董事薪酬方案的议案 ....... 12 议案五：圣湘生物科技股份有限公司关于聘任公司 2025 年度财务审计机构及内 议案六：圣湘生物科技股份有限公司关于提请股东大会授权董事会制定并执行 议案八：圣湘生物科技股份有限公司关于 2025 年度监事薪酬方案的议案 ....... 21 议案九：圣湘生物科技股份有限公司关于增资湖南圣维鲲腾生物科技有限公司暨 圣湘生物科技股份有限公司（688289）2024 年年度股东大会会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》以及 《圣湘生物科技股份有限公司章程》 （以下简称"《公司章程》"） 《圣湘生物科技 股份有限公司股东大会议事规则》等相关规定，圣湘生物科技股份有限公司（以 下简称"公司"或"圣湘生物"）特制定 2024 年年度 ...

Summary of Key Points Core Viewpoint The Hong Kong IPO market has seen significant activity from May 5 to May 11, with 8 companies submitting applications, 3 companies passing hearings, 1 company going public, and 3 companies listing. Group 1: IPO Applications - A total of 8 companies submitted IPO applications, including Zhongqi Yunlian, MIRXES, YS Intelligent, Xidi Zhijia, Tong Shifu, Zhejing Electronics, Zhongding Integration, and Fuyou Payment [2][3] - Zhongqi Yunlian, established in 2015, is a leading independent digital financial platform in China, with a projected revenue of 6.52 billion RMB in 2022, increasing to 9.91 billion RMB by 2024 [3] - MIRXES, founded in 2014, specializes in miRNA technology for disease screening, with projected revenues of approximately 177.59 million USD in 2022, growing to 202.83 million USD by 2024 [4][5] - YS Intelligent, focusing on AI-driven pharmaceutical solutions, has raised over 500 million USD from notable investors and has a post-money valuation of 1.33 billion USD [6] - Xidi Zhijia, a provider of autonomous driving solutions, reported revenues of 310.56 million RMB in 2022, expected to reach 410 million RMB by 2024 [7] - Tong Shifu, established in 2013, leads the copper cultural products market in China with a 35% market share, projecting revenues of 503 million RMB in 2022 [8] - Zhejing Electronics, a pioneer in smart cockpit solutions, reported revenues of approximately 214 million RMB in 2022, with expectations of growth [9] - Zhongding Integration, a provider of smart logistics solutions, reported revenues of approximately 1.643 billion RMB in 2022, with a projected increase [11] - Fuyou Payment, a digital payment technology platform, reported revenues of approximately 1.142 billion RMB in 2022, with growth anticipated [12] Group 2: Companies Passing Hearings - Heng Rui Pharmaceutical, a leading innovative pharmaceutical company, reported revenues of 21.275 billion RMB in 2022, expected to grow to 27.985 billion RMB by 2024 [13][14] - Ningde Times, a leader in battery manufacturing, is expected to raise between 4 billion to 5 billion USD in its IPO, with a market share of 37.9% in the global battery market by 2024 [15][16] - Jihong Co., a dual-driven company in cross-border e-commerce and paper packaging, reported revenues of 5.376 billion RMB in 2022, with growth expected [17] Group 3: IPO and Listings - Green Tea Group is set to launch its IPO, offering 168 million shares at a price of 7.19 HKD per share, with significant interest from cornerstone investors [18] - Boleton, listed on May 7, priced at 18 HKD per share, saw a closing price of 24.9 HKD, reflecting a 38% increase [19] - Hu Shang Ayi, listed on May 8, had an opening price of 190.6 HKD, closing at 158.4 HKD, a 40.03% increase from its issue price [20] - Jun Da Co., also listed on May 8, opened at 22.2 HKD and closed at 26.6 HKD, marking a 20.09% increase [20] Group 4: Market Developments - The Hong Kong Stock Exchange has launched a "Tech Company Fast Track" to facilitate IPO applications for technology and biotech companies, allowing for confidential submissions [21]

将投中网设为"星标⭐"，第一时间收获最新推送 在硬科技、生物科技、新能源/绿色科技这三大投资赛道上，港投公司展现出了前瞻性布局眼光。 作者丨 高雅 编辑丨 冯迪凡 来源丨 第一财经 在全球经济格局充满不确定性的当下，投资机构如何在波动中寻找机遇？ 作为中国香港特区政府重点打造的战略投资平台，香港投资管理有限公司（以下简称"港投公司"）正 以其独特的定位和清晰的战略给出答案。 这家被业界誉为"港版淡马锡"的投资机构初始管理规模达 620 亿港元，由香港特区行政长官李家超 在首份《施政报告》中亲自规划，旨在通过直接投资或与私募基金合作，吸引重点企业落户香港，在 争取长期投资回报的同时，推动金融科技、人工智能、生物科技、高端制造业等四大核心领域发展。 在硬科技、生物科技、新能源 / 绿色科技这三大投资赛道上，港投公司展现出了前瞻性布局眼光。该 公司行政总裁陈家齐在接受第一财经独家专访时分享了她的洞察："优秀的科技公司无论在什么经济 周期中都会崭露头角。历史上许多成功的公司，之所以能一路走来，是因为它们选择了正确的发展路 径，并解决了市场上的核心痛点。" 她认为，从历史来看，最具创新能力的科技机构，通常都是解决市场上 ...

Group 1 - The private equity issuance market has seen a significant increase in activity, with nearly 3,500 new private securities investment funds registered this year, representing a nearly 40% growth compared to the same period last year [1] - NIO plans to issue H-shares at a maximum price of 263 HKD per share, with the pricing expected between May 13 and May 16, and trading to commence on May 20 [1] - A trend of consumer companies going public overseas has emerged, with several new consumption brands planning listings in Hong Kong and the US, driven by the need for international expansion and brand enhancement [1] Group 2 - Shanghai Ladder Medical Technology has successfully conducted a clinical trial of an invasive brain-computer interface system, allowing a participant to control a game using thoughts after implant surgery [2] - Samsung has reportedly reached an agreement with major clients to increase DRAM prices, with DDR4 prices rising by double-digit percentages and DDR5 prices increasing by single-digit percentages [2] - Polestar is recalling 3,664 vehicles in the US due to a rearview camera issue that may reduce driver visibility, with software updates planned to address the problem [2] Group 3 - Specialized Medical Company in Saudi Arabia successfully completed a $500 million IPO, with all shares sold within hours, indicating strong demand [3] - Mirxes Holding Company Limited has passed the listing hearing at the Hong Kong Stock Exchange, focusing on miRNA technology for cancer screening [4] Group 4 - Huiyuan Juice has issued a statement refuting rumors about its financial difficulties, emphasizing that such claims are malicious and damaging to its reputation [5] - Hualan Biological Engineering announced that its major shareholder plans to reduce its stake by up to 3% within three months [6] - Pilin Bio received an administrative regulatory decision from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [7] Group 5 - ST Jinke has received court approval for its restructuring plan, allowing the company and its subsidiary to enter the execution phase of the plan [8]

Core Viewpoint - Beijing Ningmei Haowei Biotechnology Co., Ltd. has completed tens of millions in angel round financing to support research and industrialization in gene-edited cell therapy, focusing on clinical applications in precision anti-aging and chronic disease treatment such as diabetes [1][4] Group 1: Company Overview - Ningmei Haowei was founded in 2015 and aims to provide comprehensive precision medical and health management solutions from disease prevention and diagnosis to treatment, leveraging cutting-edge life science technologies [1] - The founding team consists of top domestic and international experts in life sciences and clinical medicine, with over a decade of experience in cell research and gene therapy, achieving multiple breakthrough research results [1] Group 2: Precision Medical Ecosystem - The company has established a precision medical ecosystem driven by "cell + gene" technology, covering the entire lifecycle [3] - Precision Anti-aging: Offers personalized anti-aging solutions through cell preparation and immune cell storage services based on leading global cell technology research and industrialization platforms [3] - Chronic Disease Treatment: Actively promotes stem cell therapy for major chronic diseases such as diabetes, cardiovascular diseases, and neurological disorders, collaborating with clinical institutions for efficacy evaluation to ensure treatment safety and durability [3] - Tumor Treatment: Focuses on gene-reprogrammed cell technology to create a comprehensive tumor cell treatment system, including personalized cell bank establishment, immune cell and stem cell differentiation preparation, and engineered cell line technology [3] Group 3: Quality Control and Future Plans - Ningmei Haowei has a strict quality control system ensuring safe cell sources with low immunogenicity and no potential infectious diseases or cancer risks, with cells stored in national authoritative institutions using top global storage equipment [4] - The company is equipped with GMP-grade independent laboratories and top-tier R&D, production, and quality inspection equipment, ensuring a sterile operating environment and automated, closed cell culture systems [4] - The recent financing will inject strong momentum into the company's R&D in cell therapy and gene editing technology, accelerating the transition of innovative therapies from laboratory research to clinical applications [4] - Future development plans include expanding the application scenarios of stem cell therapy in precision anti-aging and chronic disease treatment, continuously deepening the precision medical sector, and promoting the industrialization of cell therapy technology [4]

Core Viewpoint - The article provides an overview of recent IPO activities in Hong Kong, the US, and China, highlighting key companies and their market performance. Group 1: Company IPOs - Hu Shang A Yi officially listed on the Hong Kong Stock Exchange on May 8, 2025, with the stock code "2589," raising a total of HKD 273 million through the issuance of 2,411,340 shares, with a subscription rate of 3,616.83 times for the public offering [3][6] - Bo Le Ton Technology listed on May 7, 2025, as the first "zero-carbon mining robot" stock in Hong Kong, issuing 13 million shares with a public offering subscription rate of 198.72 times [7][8] - Green Tea Group plans to list on May 16, 2025, with an expected market capitalization of HKD 4.842 billion, aiming to raise over HKD 1.2 billion through the issuance of 168,364,000 shares [11][12] - InSilico Medicine updated its prospectus on May 8, 2025, aiming to become the first "AI-driven innovative drug" stock in Hong Kong, with a focus on drug discovery and development using AI technology [16][17] - Copper Master submitted its prospectus on May 9, 2025, aiming to list on the Hong Kong Stock Exchange, recognized as the leading brand in China's copper cultural and creative products market [20][23] - Zejing submitted its prospectus on May 9, 2025, as an innovative smart cockpit visual and interaction solution provider, ranking second in the Chinese HUD solution market with a market share of 16.2% [24][25] Group 2: Financial Performance - Hu Shang A Yi's GMV grew from CNY 6.068 billion in 2022 to CNY 10.736 billion in 2024, with revenue of CNY 2.199 billion in 2022, CNY 3.348 billion in 2023, and CNY 3.285 billion in 2024 [5] - Bo Le Ton's electric wide-body dump truck shipments increased from 59 units in 2022 to 307 units in 2024, with a compound annual growth rate (CAGR) of 128.1% [9] - Green Tea Group's revenue increased from CNY 2.375 billion in 2022 to CNY 3.838 billion in 2024, with a net profit of CNY 0.17 billion in 2022 and CNY 0.35 billion in 2024 [13] - InSilico Medicine's revenue grew from USD 30.15 million in 2022 to USD 85.83 million in 2024, with a gross margin increasing from 63.4% to 90.4% [18] - Copper Master achieved revenue of CNY 503 million in 2022, CNY 506 million in 2023, and CNY 571 million in 2024, with a net profit margin of 13.8% in 2024 [22] - Zejing's revenue increased from CNY 214 million in 2022 to CNY 578 million in 2024, with a CAGR of 64.3% [26][27] Group 3: Market Position and Growth - Hu Shang A Yi ranked first among mid-priced tea beverage brands in Northern China and third among all mid-priced tea beverage brands in China as of December 31, 2023 [4] - Bo Le Ton ranked third among all new energy wide-body dump truck manufacturers in China, with a market share of 18.3% [8] - Green Tea Group ranked third in the number of restaurants and fourth in revenue among casual Chinese restaurant brands in mainland China as of 2024 [12] - InSilico Medicine's Pharma.AI platform is recognized as a leading AI-driven drug discovery and development platform globally [17] - Copper Master holds a 35% market share in the copper cultural and creative products market in China as of 2024 [21] - Zejing is the only Chinese supplier to have received multiple international mainstream OEM orders for HUD solutions, achieving significant market penetration [25]

2025.05. 11 本文字数：2469，阅读时长大约4分钟 作者 | 第一财经 高雅 在全球经济格局充满不确定性的当下，投资机构如何在波动中寻找机遇？ 作为中国香港特区政府重点打造的战略投资平台，香港投资管理有限公司（以下简称"港投公司"）正 以其独特的定位和清晰的战略给出答案。 这家被业界誉为"港版淡马锡"的投资机构初始管理规模达620亿港元，由香港特区行政长官李家超在 首份《施政报告》中亲自规划，旨在通过直接投资或与私募基金合作，吸引重点企业落户香港，在争 取长期投资回报的同时，推动金融科技、人工智能、生物科技、高端制造业等四大核心领域发展。 在硬科技、生物科技、新能源/绿色科技这三大投资赛道上，港投公司展现出了前瞻性布局眼光。该 公司行政总裁陈家齐在接受第一财经独家专访时分享了她的洞察："优秀的科技公司无论在什么经济 周期中都会崭露头角。历史上许多成功的公司，之所以能一路走来，是因为它们选择了正确的发展路 径，并解决了市场上的核心痛点。" 她认为，从历史来看，最具创新能力的科技机构，通常都是解决市场上核心痛点的企业，它们能在不 同的经济周期中脱颖而出。现在正是抓住这一窗口，快速寻找优秀伙伴和公司的好 ...

Group 1 - Warren Buffett, at 94 years old, announced his retirement at the Berkshire Hathaway annual meeting, with Greg Abel set to take over as CEO [1] - Berkshire Hathaway has reduced its stock holdings for the 10th consecutive quarter, accumulating a record cash reserve of $347.7 billion (approximately 2.53 trillion RMB) [1] - The transition raises questions about how the multi-trillion dollar empire will be divided [1] Group 2 - Buffett's investment philosophy emphasizes "value investing" and "compound miracles," with a focus on making a few precise investments [3] - Notable investments include a significant stake in American Express during a crisis and a $36 billion investment in Apple, yielding over $155.6 billion in total returns [3] - Buffett has also invested in a biotechnology venture targeting male vitality, which has gained traction in the market [6] Group 3 - The biotechnology product "被他强" has shown explosive growth, with a user repurchase rate exceeding 70% within a year of launch [7] - The product targets age-related declines in male vitality and has attracted interest from wealthy investors in China [6][7] - Buffett noted that opportunities to convert physiological desires into investment chances are rare [7] Group 4 - Buffett's personal lifestyle choices, including a diet of ice cream and fast food, have been humorously labeled as "anti-health," yet he remains in good health [9] - His approach to marriage and wealth distribution is strategic, with a unique trust structure for his children and a significant portion of his wealth directed to charity [10] Group 5 - Following Buffett's retirement announcement, speculation arises regarding the management of Berkshire's substantial cash reserves, with some analysts predicting a potential market downturn [12] - Greg Abel, known for his cost-cutting strategies, faces the challenge of effectively utilizing the $2.5 trillion cash reserve [12] - The retirement of Buffett prompts discussions about whether it marks the end of an era or the beginning of a new chapter for Berkshire Hathaway [12]

最具创新能力的科技机构能在不同的经济周期中脱颖而出。 在全球经济格局充满不确定性的当下，投资机构如何在波动中寻找机遇？ 这家被业界誉为"港版淡马锡"的投资机构初始管理规模达620亿港元，由香港特区行政长官李家超在首 份《施政报告》中亲自规划，旨在通过直接投资或与私募基金合作，吸引重点企业落户香港，在争取长 期投资回报的同时，推动金融科技、人工智能、生物科技、高端制造业等四大核心领域发展。 在硬科技、生物科技、新能源/绿色科技这三大投资赛道上，港投公司展现出了前瞻性布局眼光。该公 司行政总裁陈家齐在接受第一财经独家专访时分享了她的洞察："优秀的科技公司无论在什么经济周期 中都会崭露头角。历史上许多成功的公司，之所以能一路走来，是因为它们选择了正确的发展路径，并 解决了市场上的核心痛点。" 她认为，从历史来看，最具创新能力的科技机构，通常都是解决市场上核心痛点的企业，它们能在不同 的经济周期中脱颖而出。现在正是抓住这一窗口，快速寻找优秀伙伴和公司的好时机。 在风险中寻找科技投资机遇 第一财经：在全球经济不确定性加剧的背景下，港投如何在当前全球市场动荡中布局？如何在三大重点 赛道中平衡风险与机会？ 陈家齐：投资本身 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched a "Tech Company Fast Track" to facilitate the listing of specialized technology and biotech companies, addressing previous regulatory gaps and enhancing Hong Kong's position as a preferred listing destination for innovative firms [1][2][3]. Group 1: Introduction of "Tech Company Fast Track" - The "Tech Company Fast Track" was officially announced on May 6, 2023, by the Hong Kong Securities and Futures Commission and HKEX, allowing companies to submit listing applications confidentially [1]. - This initiative is part of a broader strategy to attract more technology companies to the Hong Kong market, leveraging its unique advantages in connecting with both international and mainland Chinese investors [2][8]. Group 2: Addressing Concerns of Tech Companies - The new listing framework aims to alleviate concerns among tech companies regarding regulatory uncertainties and the adequacy of existing rules (18A and 18C) [3][4]. - Companies have expressed worries about the disclosure of sensitive information during the listing process, which could jeopardize their intellectual property [5][6]. Group 3: Market Trends and Investor Dynamics - The HKEX has observed a significant contribution from companies listed under the 18A and 18C rules, accounting for 80% of market financing in 2024 [7]. - The Hong Kong market is seen as advantageous due to its international financial center status and the presence of mechanisms like Stock Connect, which facilitate access for mainland investors [8]. Group 4: Recent Activity and Future Outlook - The first quarter of 2023 saw robust trading activity on the HKEX, with 16 trading days exceeding HKD 300 billion in transaction volume, indicating a healthy IPO environment [8][9]. - The market is experiencing a resurgence in interest from both established and emerging tech companies, particularly in the AI sector, with numerous IPOs and refinancing activities taking place [9].